Visceral Leishmaniasis Clinical Trial
Official title:
Improved Visceral Leishmaniasis (VL) Case Detection and Vector Control to Support the VL Elimination Initiative in Bangladesh
Visceral leishmaniasis (VL) also known as kala-azar is a public health problem in Bangladesh.
Since 2005 a national kala-azar elimination program is going on in the country. The program
has preparatory, attack, consolidation and maintenance phases. The target of the program is
to reduce the VL incidence less than 1 per 10,000 people at upazila (sub-district) level in
VL endemic upazilas of the country. The program is heading successfully to its consolidation
phase.
During attack phase house to house search for VL suspects and also suspects with
Post-kala-azar Dermal Leishmaniasis (PKDL) was the tool for early diagnosis of VL and PKDL
cases. Indoor residual spraying with insecticide (Deltamethrin) was the method for sand fly
control to reduce the transmission of the disease. Since in the consolidation phase the VL
case load is many times less than that in the attack phase, house to house search for VL and
PKDL cases and IRS for vector control is no more cost-effective for the program. Therefore
there is a need for alternative methods for active search of VL and PKDL cases and method for
sand fly control, appropriate for the consolidation phase.
In the present study the investigators propose to investigate the efficacy of Inesfly 5AIGRNG
TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%), commercial
available durable wall lining (DWL), impregnated of existing bed-net with insecticide tablet,
KO TAB 123, indoor residual spraying (IRS) with Delthamethrin against a control group
Methods: A cluster randomized controlled design to measure sand fly density reduction at
intervention household as well as sand fly mortality by entomological methods.
Outcome measures/variables: reduction of sand fly density at intervention household and sand
fly corrected mortality on intervention surfaces compare to control households/conditions.
The objective of this study is to test the efficacy Inesfly 5AIGRNG TM containing
Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%), and other intervention
with control group. The formulation is vinyl paint with an aqueous base, with the active
ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of
active ingredients. Microcapsules range from one to several hundred micrometers in size.
Inesfly has been tested for control of malaria and chagas disease vector with encouraging
results. The product is effective even against vectors, resistant to pyrethroids.
A randomized control trial will be performed with Inesfly 5AIGRNG TM containing
Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%), commercial available
durable wall lining (DWL), impregnated of existing bed-net with insecticide tablet, KO TAB
123, indoor residual spraying (IRS) with Delthamethrin against a control group (study with 5
arms). The study will be carried out in villages located in Mymensingh District , one of the
high VL endemic district in Bangladesh. The VL burden of the villages will be estimated using
the VL case reports in the last 12 months. Four high endemic villages will be selected for
the study. As per sample size calculation the investigators need minimum 31 households to see
the efficacy of the interventions (see sample size calculation part below). The investigators
will include 50 households for each intervention and 50 for control (No intervention).
Twenty-five households (HHs) from each village will be selected randomly which will be
considered as a cluster. Field Research Assistant will be listed all the study households.
Only subjects who agree to participate and freely signed the consent form will be included in
the study. Household roster and household head interview for socio-demographic,
socio-economic and knowledge about VL and VL vectors will be done. Based on sample size
calculation, 18 HHs from each cluster will be selected randomly for entomological analysis
which includes sand fly density measurement (base line and 1, 3, 6, 9,12, 15, 18, 21 and 24
months after intervention), WHO Cone bioassay on the intervention surfaces and control
surfaces at 1, 3, 6, 9,12, 15, 18, 21 and 24 months after intervention After performing
baseline sand fly density measurements, clusters will be redefined with High density (sand
fly density =>50th percentile), and low (sand fly density (<50th percentile). One cluster
will be selected randomly from each density group for the intervention with Inesfly,
commercial DWL, and the control group with no intervention. All groups will receive the
routine vector control services by the national program. Acceptability survey of the
intervention will be conducted at 6 weeks since intervention to see the community acceptance
of the intervention.
Entomological methods:
Sand fly collection and density measurement For the entomological activities for objective 2
and objective 3 HH head will be informed and his/her informed, written voluntary consent will
be obtained before the start of any activities. HH head and members will be requested one day
before by the research team to make space for conduct installation of DWL / wall paining with
Inesfly by removing materials including furniture to a safe place. They also will be informed
that for entomological activities i.e. for collection of sand fly by CDC light trap research
team will visit the HH for two consecutive days as on day one they will visit in the evening
to place CDC light trap in a corner of the main room and to take it out on the following
morning. As sand fly collection will be done before intervention and at 1 month, 6 months and
12 months after intervention research team will visit the HH 4 times for sand fly collection.
In addition to conduct the WHO Cone bioassay test which will be done again at 1 month, 3
months and 12 months since intervention the HH will be visited again 3 times by the research
team.
Sand flies will be collected on two consecutive nights with CDC light traps by trained
personnel with guidance from a member of the study team. Light traps will be kept in a corner
from 6 pm to 6 am, 2 inch away from the wall with a distance of 6 inches between the floor
and the bottom of the sac. The sand fly density will be expressed as number of P. argentipes
per light trap per night. Sand fly identification will be done as follows:
- Upon collection, sand flies will be segregated and labeled by batch indicating the date
and the pre-printed batch numbers. Sand fly numbers and sex will be identified under
microscope.
- Morphological identification will be done in the field using the following criteria:
vi. Phlebotomus argentipes Pa: Black thorax+silvering shining of the tarsal tip of the
leg+3mm.
vii. Phlebotomus papatasi Pp: Brown to yellow thorax+3mm. viii. Sergentomyia sp Sr:I1-2mm c.
Sex and physiological status ix. Males: external genitalia with claspers x. Females: without
claspers, Blood-fed, unfed, gravid (no undigested blood).
WHO Cone Bioassay Test The WHO cone bioassays will be performed using the cone method (WHOPES
2005.11) on treated and non-treated bed-nets with wild caught (manually collected) sandflies
at 1 month, 6 months and 12 months after intervention. Bioassays will be carried out at room
temperature at 25o- 29oC and 75-85% humidity. Resting sandflies will be collected manually by
aspirator during early morning and evening. In each net, 10-12 female sand flies will be
introduced in each of the cones placed against the DWL / Wall for 30 minutes. The sand flies
will be then transferred from each cone to a paper cup for observation. They will be observed
over 24 hours to calculate the mortality. The mortality rates of sand flies will be corrected
with Abbot's formula (WHOPES 2005.11).
Measurement of efficacy of interventions: Efficacy will be defined by the reduction of
sandfly density by intervention compared to control measured by sandfly density at 1 months,
6 months and 12 months after intervention; percentage mortality of sand-fly assessed by WHO
Cone Bioassay test on DWL and wall after 1 months, 6 months and 12 months following
intervention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02839603 -
Asymptomatic Leishmania Infection in HIV Patients
|
||
Completed |
NCT00370825 -
Combination Chemotherapy for the Treatment of Indian Kala-Azar
|
Phase 2 | |
Recruiting |
NCT05426577 -
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
|
||
Completed |
NCT01069198 -
A Community Trial for Visceral Leishmaniasis (VL)
|
N/A | |
Completed |
NCT00604955 -
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
|
Phase 4 | |
Completed |
NCT01032187 -
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
|
Phase 4 | |
Completed |
NCT00371995 -
Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar
|
Phase 2 | |
Completed |
NCT00342823 -
Immunogenetics of Visceral Leishmaniasis
|
N/A | |
Completed |
NCT04003532 -
LAMP Assay for the Diagnosis of Visceral Leishmaniasis
|
||
Terminated |
NCT01980199 -
Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan
|
Phase 2 | |
Completed |
NCT00255567 -
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
|
Phase 3 | |
Not yet recruiting |
NCT06118749 -
Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study
|
||
Recruiting |
NCT04342715 -
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
|
||
Completed |
NCT02431143 -
Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa
|
Phase 2 | |
Completed |
NCT01122771 -
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
|
Phase 3 | |
Completed |
NCT03636659 -
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
|
Phase 1 | |
Not yet recruiting |
NCT01566552 -
Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
|
Phase 4 | |
Completed |
NCT00696969 -
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
|
Phase 3 | |
Completed |
NCT00318721 -
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
|
N/A | |
Completed |
NCT00216346 -
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
|
Phase 3 |